Elekta AB

Elekta AB is a global leader in precision cancer care, specializing in radiotherapy and radiosurgery systems for oncology treatment. With over 50 years of experience, the company develops advanced solutions for adaptive radiotherapy—a precision treatment approach that adjusts to patient anatomy changes during therapy. Elekta's product portfolio includes linear accelerators for external beam radiotherapy, the Leksell Gamma Knife for stereotactic radiosurgery, and integrated imaging and software systems for treatment planning and guidance. The company serves cancer centers and hospitals worldwide, addressing multiple tumor types including head and neck, breast, prostate, brain, gynecological, kidney, and pancreatic cancers. Elekta's adaptive radiotherapy platform combines daily imaging, AI-assisted planning, and real-time treatment adjustment to optimize dose delivery while protecting healthy tissue. The company supports clinical workflows with comprehensive software solutions for treatment planning, image guidance, and outcome tracking. Elekta maintains a strong commitment to clinical evidence generation and supports leading oncology institutions globally. As a publicly traded company headquartered in Sweden, Elekta operates a global infrastructure including manufacturing, service centers, and training facilities. The organization emphasizes precision medicine innovation and advancing radiotherapy as a standard of care across diverse patient populations and healthcare settings.